CAM
VIR icon

Cresset Asset Management’s Vir Biotechnology VIR Stock Holding History

Cresset Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,350
Closed -$112K – 1790
2025
Q1 		$112K Sell
17,350
-7,859
-31% -$69.9K ﹤0.01% 1606
2024
Q4 		$185K Sell
25,209
-5,681
-18% -$44.8K ﹤0.01% 1578
2024
Q3 		$231K Sell
30,890
-7,718
-20% -$67K ﹤0.01% 1926
2024
Q2 		$344K Sell
38,608
-4,438
-10% -$42.6K ﹤0.01% 1644
2024
Q1 		$436K Sell
43,046
-83,869
-66% -$854K ﹤0.01% 1404
2023
Q4 		$1.28M Buy
126,915
+37,741
+42% +$345K 0.01% 789
2023
Q3 		$836K Buy
89,174
+22,937
+35% +$327K ﹤0.01% 940
2023
Q2 		$1.62M Buy
+66,237
New +$1.66M ﹤0.01% 715

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cresset Asset Management's VIR Position: Q2 2025 in Review

Cresset Asset Management sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 17,350 shares — an estimated $112K sold.

Cresset Asset Management first reported a position in VIR in Q2 2023 and held it in 8 quarters. The position peaked at $1.62M in Q2 2023. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Cresset Asset Management reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Cresset Asset Management sold 17,350 Vir Biotechnology shares in Q2 2025, an estimated $112K.
  • Cresset Asset Management first reported a position in Vir Biotechnology in Q2 2023 and held it in 8 quarters.
  • Cresset Asset Management's Vir Biotechnology position peaked at $1.62M in Q2 2023.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Cresset Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.